NASDAQ: DRNA - Dicerna Pharmaceuticals, Inc.

Lønnsomhet i seks måneder: 0%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Dicerna Pharmaceuticals, Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Dicerna Pharmaceuticals, Inc.

Биофармацевтическая компания Dicerna Pharmaceuticals, Inc. специализируется на открытии и разработке фармацевтических препаратов на основе интерференции рибонуклеиновой кислоты (РНКи). Компания разрабатывает фармацевтические препараты с использованием своей платформы GalXC RNAi для лечения заболеваний печени, включая редкие заболевания, вирусные инфекционные заболевания, хронические заболевания печени и кардиометаболические заболевания.

flere detaljer
Его основные программы развития включают недосиран для лечения первичной гипероксалурии; RG6346 для лечения хронической инфекции вируса гепатита B; и программа лечения нераскрытого редкого заболевания печени. В программы развития компании также входят программы DCR-A1AT; и программа лечения нейродегенерации и боли. Dicerna Pharmaceuticals, Inc. имеет стратегическое сотрудничество с Novo Nordisk A \ u002FS, Roche, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc. и Boehringer Ingelheim International GmbH. Компания была основана в 2006 году, ее штаб-квартира находится в Лексингтоне, штат Массачусетс.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2014-01-30
ISIN US2530311081
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://dicerna.com
Цена ао 37.96
Prisendring per dag: 0% (38.22)
Prisendring per uke: 0% (38.22)
Prisendring per måned: 0% (38.22)
Prisendring over 3 måneder: 0% (38.22)
Prisendring over seks måneder: 0% (38.22)
Prisendring per år: 0% (38.22)
Prisendring over 3 år: +0.6849% (37.96)
Prisendring over 5 år: +43.58% (26.62)
Prisendring over 10 år: +94.6% (19.64)
Prisendring siden begynnelsen av året: 0% (38.22)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 15.2 1
P/BV 27.7 1
P/E 0 0
EV/EBITDA -20.9 0
Total: 1.5

Effektivitet

Navn Betydning Karakter
ROA, % -17.12 0
ROE, % -95.22 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.5518 10
Total: 10

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 8286.96 10
Lønnsomhet Ebitda, % 99.83 9
Lønnsomhet EPS, % -41.61 0
Total: 5.8
Flere detaljer

Institusjoner Volum Dele, %
RTW INVESTMENTS, LLC 7521859 9.68
BlackRock Fund Advisors 5620264 7.36
SSGA Funds Management Inc 4083964 5.25
Bain Capital Life Sciences Investors, LLC 3080237 3.96
Aquilo Capital Management, LLC 1813392 2.33
Candriam Belgium 1143680 1.5
Polar Capital LLP 1084813 1.4
Hartford Funds Management Company, LLC 891613 1.15
Federated MDTA LLC 853626 1.1
Advanced Series Trust 646199 0.84
Invesco Capital Management LLC 605461 0.78
Dafna Capital Management LLC 510756 0.66
AXA Investment Managers UK Ltd 319319 0.43
Parkman Healthcare Partners LLC 304686 0.39
Voya Investments, LLC 302733 0.39
Global X Management Company LLC 253113 0.33
SILVERARC CAPITAL MANAGEMENT, LLC 229892 0.3
Brighthouse Investment Advisers, LLC 225796 0.29
Driehaus Capital Management LLC 198720 0.26
Lyxor International Asset Management S.A.S. 178369 0.23
MML Investment Advisers, LLC 169354 0.23
Eagle Health Investments LP 161125 0.21
Prudential Retirement Services 143262 0.19
Evolutionary Tree Capital Management LLC 141324 0.18
Schroder Investment Management Limited 140884 0.18
UBS Asset Management (Americas) Inc 119782 0.15
Arctic Asset Management AS 97907 0.13
Bellevue Asset Management AG 68000 0.09
AMG Funds LLC 65706 0.09
SunAmerica Asset Management, LLC 48970 0.06
Allianz Global Investors 42967 0.06
Migdal Mutual Funds Ltd 28720 0.04
Allianz Global Investors U.S. LLC 26035 0.03
IP Unsure (Only US OE Use) 18034 0.02
361 Capital, LLC 13440 0.02
AXA Investment Managers Paris 10923 0.01
DNB Asset Management AS 8015 0.01
Severin Investments, LLC 7650 0.01
Santander Private Banking Gestión SGIIC 4164 0.01
Glenmede Investment Management, LP 1200 0
Peroni Portfolio Advisors, Inc 500 0

ETFDele, %Lønnsomhet for året, %Utbytte, %
ProShares UltraShort Nasdaq Biotechnology 0.18 -40.36 1.76
0.18-40.361.76



Veileder Stillingstittel Betaling Fødselsår
Dr. Douglas M. Fambrough III Co-Founder, CEO, Pres & Director 939.47k 1969 (56 år)
Mr. Douglas W. Pagan Chief Financial Officer 515.65k 1972 (53 år)
Mr. James B. Weissman Exec. VP & COO 648.77k 1962 (63 år)
Dr. Bob D. Brown Exec. VP of R&D and Chief Scientific Officer 695.89k 1965 (60 år)
Dr. Shreeram Aradhye M.D. Exec. VP & Chief Medical Officer 434.4k 1963 (62 år)
Dr. Mark Behlke Co-Founder & Member of Scientific Advisory Board N/A
Ms. Ling Zeng J.D. Chief Legal Officer & Sec. N/A 1969 (56 år)
Prof. John J. Rossi Ph.D. Co-Founder & Chairman of Scientific Advisory Board 1947 (78 år)
Ms. Kristen K. Sheppard Esq., J.D. Sr. VP of Investor Relations & Corp. Communications
Ms. Susan Birdsey SPHR Sr. VP of HR

Adresse: United States, Lexington, MA , 75 Hayden Avenue - åpne i Google maps, åpne Yandex-kart
Nettsted: http://dicerna.com